CLINT1

Across TCGA pan-cancer cohorts, CLINT1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CLINT1 data layer compared with 27 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLINT1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CLINT1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and GBM are the cancer types where CLINT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.931	0.774	.001	69	view →
COAD	DFS	Median	All	1.000	0.886	.020	36	view →
GBM	DFS	Tertile	All	0.568	0.863	<.001	20	view →
CCRCC	OS	Tertile	II,III,IV	0.989	0.133	.020	11	view →
UCEC	OS	Median	All	1.000	0.905	.009	10	view →
LUAD	DFS	Tertile	III,IV	0.555	0.972	.016	6	view →
LSCC	DFS	Median	All	0.869	0.724	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CLINT1–PDAC (OS)

Open the PDAC breakdown →